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Objective: The aim of this study was to analyse the diagnostic accuracy
and the clinical usefulness of combination of troponin and copeptin for rapid
rule out of non ST elevation myocardial infarction (NSTEMI) diagnosis in
Emergency Department (ED).
Method: This study was an ancillary analysis of a prospective 11 months
observational study. Consecutive patients admitted to an university ED for chest
pain within 12 hours of ED presentation and without ST elevation on a 12-lead
ECG were eligible. Blood samples for determination of copeptin were frozen
at –80°C until assayed in a blinded fashion. Patients were classified by two inde-
pendent physicians (kappa=0.72) as having acute coronary syndrome (ACS) and
NSTEMI if cTnI was above 0.1 μg/L on serial testing. Performance of combina-
tion of cTnI and copeptin for NSTEMI diagnosis at presentation was studied and
clinical utility was assessed by multivariate analysis, area under the curve (AUC)
calculation for accuracy, and reporting operating characteristics with 95% confi-
dence intervals.
Results: Out of the 641 eligible patients who were recruited, non-ST
elevation ACS was diagnosed in 180 patients (28%) including 95
NSTEMI. The negative predictive value of the combination of copeptin
and cTnI measures was 97.6% (95% CI 96.4-98.7) versus 92.8% (95%CI
90.8-94.8) with cTnI alone. The patient classification was significantly
improved when copeptin was added to the usual diagnostic tools used for
NSTEMI management: the AUC of the model with cTnI alone and with
cTnI and copeptin were 0.92 (95%CI 0.89-0.95) and 0.94 (95%CI 0.9-
0.96) respectively, p<0.05.
Conclusion: Combination of copeptin and troponin allows a rapid rule out of
NSTEMI at admission in ED and improves the early triage of patients with chest
pain.
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Aim:To evaluate the prognostic value at 6 months (m) of residual pulmo-
nary vascular obstruction (RPVO) measured at discharge in pts with inter-
mediate- or high-risk PE.
Methods: 416 consecutive pts with intermediate- or high-risk PE who
survived the acute phase were prospectively included. Pts with known
cardiopulmonary disease were excluded. Perfusion lung scans were per-
formed within 6-8 days after onset of treatment. RVPO was graded as the
proportion of lung not perfused. Primary objective was a combined end-
point at 6 m, including death, recurrent PE, appearance of signs of heart
failure (HF).
Results: At 6m, 32 patients (7.7%) had 1 adverse event: 15 deaths
(3.6%), 12 recurrent PE (2.9%), 14 cases (3.4%) of HF. Independent predic-
tors of combined endpoint were: cancer (odds ratio (OR) 4.51 [1.63-12.5]);
presence of >=1 risk factor for venous thrombo-embolic disease (OR 4.42
[1.53-12.8]); renal insufficiency at admission (OR 2.91 [1.16-7.27]); persistent
ECG signs of cor pulmonale (OR 3.2 [1.11-9.24]); and persistent echographic
signs of RV dysfunction (OR 4.99 [1.46-16.31]). Severity of RPVO at dis-
charge was significantly associated with unfavorable outcome (OR 2.56 [1.69-
3.87]). The incremental prognostic value of the RVPO information was con-
firmed by a decrease in the Akaike criterion, and increases in indices of cali-
bration and discrimination when RVPO was added to the multivariate model.
The threshold RVPO value for predicting adverse events was estimated at
35% (figure). Pts with RVPO >threshold at discharge had a significantly
higher risk of death at 6m (p=0.01).
Conclusion: RPVO evaluated before hospital discharge in pts with
intermediate- to high-risk PE is a powerful prognostic factor for outcome
at 6m. RPVO 35% is associated with an increased risk of adverse events
at 6m.
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Paroxysmal supraventricular tachycardia (SVT) is considered as benign.
The purpose of the study was to report the prevalence of SVT-related adverse
events.
Methods: 1269 patients (pt), aged from 6 to 93 years with a normal ECG
in sinus rhythm were recruited for SVT, confirmed by electrophysiological
study. Pts with anterograde conduction through accessory pathway (AP) were
excluded. SVT-related adverse events were collected.
Results: Adverse event occurs in 207 pts (16%) (group I, gr); 10 of them
had a very serious event (gr I A): resuscitated ventricular fibrillation was pro-
voked by SVT in 1 pt with coronary heart disease (HD), 1 pt with hyper-
trophic cardiomyopathy; 1 pt 55 years old, with respiratory failure, died after
a prolonged SVT. Six pts presented resuscitated cardiac arrest after anti-
arrhythmic drugs used to stop SVT (sotalol, verapamil). 197 pts presented
with a poorly-tolerated SVT (gr I B), syncope (148), acute coronary syndrome
(36), tachycardiomyopathy (6), stage IV of heart failure (5), inappropriate
shock at ICD (1), collapsus after verapamil (1). Gr I was compared to pts
without adverse events (gr II). Gr I was older than gr II (55±20 vs
49±18 years)(p<0.003). Male gender was more frequent in gr IB (53%) than
in gr II (38%) (p<0.02). Underlying HD was more frequent in gr I (32%) than
in gr II (6%) ( p<0.0000). The rate in tachycardia did not differ (183±41 bpm
in gr I, 186±35 in gr II). SVT mechanism was similar: reentry in a concealed
AP was noted in 19 % of gr I and II. Typical and atypical AV nodal reentrant
tachycardias represented other causes. In gr II, 2 ablation-related deaths in old
women and one sudden death 2 months after ablation were noted among 663
patients who had SVT ablation.
Conclusions: SVT-related adverse events occurred in 16% of patients.
Advanced age, male gender and presence of HD were predisposing factors.
However, life-threatening arrhythmias were rare and represented less than 1
%. Most of them were drug-related. 
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Aims: Due to its prolonged declining clinical effect, levosimendan might
help in weaning patients dependent on inotropes. We assessed the effect of a
24-hour infusion of levosimendan in a cohort of advanced heart failure
patients dependent on dobutamine or milrinone.
Methods: In this prospective observational study, 71 patients (pts), aged
58 [IQR: 44-63] years with advanced heart failure (28 ischaemic) and depen-
dant on inotropes (define as failure of >2 consecutive trials in 7 days; dob-
utamine n=62, milrinone n=9) were included. They received a 24-hour
intravenous infusion of levosimendan (0.1 μg/kg/min) in the ICU. 4 of them
had an intra-aortic balloon pump. Success was defined as “alive and free from
inotrope” at the end of ICU stay.
Results: The median time from hospital admission to beginning of levosi-
mendan infusion was 16 [IQR:5.5-29.2] days. Fifty five pts (76.1%) were
alive and free of dobutamine or milrinone 48H after initiation of levosim-
endan. Four patients failed to receive the full levosimendan amount and
9 patients (16%) had to receive norepinephrine because of hypotension. Atrial
fibrillation occurred in 9 pts (12.7%). Median time to stop dobutamine or mil-
rinone was 18 [IQR:4.5-24] hours. Reinitiation of inotropes was needed in
3 pts.
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At the end of ICU stay, success was present in 51 pts (71.8%). Median stay
in the ICU after levosimendan administration was 4 [IQR:1-9] days. A beta-
blocker and an ACE inhibitor were given in 43.1% and 74.5% respectively.
No clinical, biological or hemodynamic characteristics were predictive of
failure to wean from inotropes with levosimendan. Overall, 13 pts (18%) died
in the ICU and another 12 (17%) died after leaving the ICU during their hos-
pital stay. Heart transplantation was performed in 16 patients within 6 months,
13 of them were in the success group. Failure to wean from inotropes within
48 hours of levosimendan administration was a strong predictor of in-hospital
mortality (64% vs 27%; p=0.01).
Conclusions: In patients with advanced heart failure and dependant on
dobutamine or milrinone, levosimendan is a valuable therapeutic option to
wean these patients off intravenous inotropic support.
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Objectives: We sought to evaluate the impact of post-primary percuta-
neous coronary intervention (PCI) patent artery in the infarct-related artery in
patients with ST-segment elevation myocardial infarction (STEMI) and car-
diogenic shock.
Background: Little is known about predictors of survival in patients with
persistent shock following STEMI despite a patent infarct artery.
Methods: This retrospective monocentric study included consecutive
patients with an early cardiogenic shock complicating STEMI from 2007 to
2010 in our center.
All these patients underwent early PCI: ie up to 36 h from symptoms and
only patients with infarct artery patency defined as final TIMI 3 flow were
included.
Results: Between 2007 and 2010, 832 patients underwent primary PCI for
acute STEMI. We studied specifically a cohort of 84 patients with cardiogenic
shock with post-procedure patent TIMI 3 infarct related artery.
The mean age of the patients was 64±13 years. The delay between STEMI
diagnosis and cardiogenic shock and open infarct related artery were 4.5 hours
and 7 hours respectively.
95% of patients underwent revascularization of the culprit lesion and mul-
tisite PCI was performed in 7% of cases.
After PCI, mechanical ventilation was used in 80% of cases and all patients
needed inotropes drugs. In two cases, a percutaneous ECMO support was
decided.
The in-hospital mortality rate was 44 %. In univariate analysis, pulmonary
insufficiency characterized by ratio PaO2/FIO2 (p=0,02), increased serum cre-
atinine (SCr) from baseline-25% (p=0,01) and level of lactates (p<0,01) were
significantly associated with increased in hospital mortality.
In multivariate analysis, the ratio PaO2/FIO2 and an increased SCr were
independent predictors of in hospital mortality.
At 6 months, the mortality rate was 46%. We noted a coronary revascular-
ization in 6 cases, a implantable cardioverter-defibrillator in 3 cases and a left
ventricular ejection fraction –35% in 20 % of patients.
Conclusion: These prognostic variables may be useful for risk-stratification
and in selecting patients for investigation of additional therapies
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Introduction: Massive pulmonary embolism is defined as occlusion of
more than 50% of the pulmonary vasculature or occlusion of two or more
lobar arteries.
Purpose of work: Describe the clinical features, paraclinical findings and
prognosis of patients with massive pulmonary embolism.
Materials and methods: It is a single-center study, retrospective, covering
145 patients hospitalized in the emergency department of the hospital Habib
Thameur in the period from January 2000 to December 2007 with a pulmo-
nary embolism. We divided our patients into 2 groups: one group with a mas-
sive pulmonary embolism (MPG+) and a group without (MPG-).
Results: The diagnosis of massive pulmonary embolism was retained in
23 patients that is 21.3%. no features patient’s specificities (age, sex and
underlying pulmonary defects) were significantly related to massive pulmo-
nary embolism. Clinical examination showed that (MPG+) had a respiratory
rate (RR) and heart rate (HR) significantly higher than the (MPG-) ( average
RR: 27 vs 23, P=0.03) (average HR: 104 vs. 95, P=0.02) .The report PaO2 /
FIO2 was significantly lower in the (MPG+) (304 vs. 358, P=0.02). The trans-
thoracic echocardiography was performed in 42 patients (8: MPG+ and 24:
MPG-), the echocardiographic characteristics which were significantly associ-
ated with massive pulmonary embolism were: right ventricular dilation
(P=0.04) and pulmonary artery hypertention (P=0.0006). Massive pulmonary
embolism was not significantly related to hospital mortality.
Conclusion: Massive pulmonary embolism does not prejudge the outcome
nether clinical consequences nor the prognostic for the patient. 
